Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Sermorelin

GHRH (1-29), GRF 1-29 NH2, Sermorelin acetate

A synthetic 29-amino acid analog of growth hormone-releasing hormone that stimulates pituitary gland to release growth hormone.

Quick Stats
Studies 223
Trials 41
Formula C149H246N44O42S
Clear All
Utility 3
pubmed 1993

Comparison of GH-stimulation by GH-RH(1-29)NH2 and an agmatine29 GH-RH analog, after intravenous, subcutaneous and intranasal administration and after pulmonary inhalation in rats.

Pinski. J J; Yano. T T; Groot. K K; Zsigo. J J; Rekasi. Z Z; Comaru-Schally. A M AM; Schally. A V AV

In rats, giving the GH‑releasing peptide sermorelin (GH‑RH 1‑29) by breathing it in (pulmonary inhalation) caused a strong rise in growth hormone, even more than a shot under the skin or a nasal spray, and the newer agmatine‑based version worked at much lower doses. This suggests inhalation could be a convenient way to boost GH, but the study is in animals, so human dosing and safety are still unknown.

Utility 3
pubmed Mar 1, 1987

Dopaminergic and cholinergic influences on the growth hormone response to growth hormone-releasing hormone in man.

Delitala. G G; Palermo. M M; Ross. R R; Coy. D D; Besser. M M; Grossman. A A

The study shows that boosting dopamine activity with a drug like bromocriptine makes the growth‑hormone‑releasing peptide (similar to sermorelin) cause a bigger GH spike, while blocking muscarinic (cholinergic) receptors reduces the spike, and blocking dopamine with domperidone doesn’t change it. This suggests dopamine helps GH release beyond the peptide itself, and cholinergic signals can dampen it.

Utility 3
pubmed Feb 1, 1986

Growth hormone response to low dose intravenous injections of growth hormone releasing factor in obese and normal weight women.

Kopelman. P G PG; Noonan. K K

In a small study, obese women showed a weaker growth‑hormone response to a single high‑dose IV shot of sermorelin compared to normal‑weight women. Giving a much lower dose in short, repeated pulses over a few hours sparked a GH rise in some obese participants who didn’t react to the big dose, while adding a final big shot didn’t help.

Utility 3
pubmed Sep 1, 1990

Decreased pituitary growth hormone response to growth hormone-releasing factor in cafeteria-fed rats: dietary and obesity effects.

Renier. G G; Gaudreau. P P; Hajjad. H H; Deslauriers. N N; Houde-Nadeau. M M; Brazeau. P P

In rats that ate a high‑calorie, junk‑food style diet, their pituitary glands became less able to release growth hormone when given growth‑hormone‑releasing factor (the same kind of peptide used in sermorelin). The more weight they gained and the longer they ate the diet, the weaker the hormone response became. This suggests that excess body fat can blunt the effectiveness of sermorelin‑type treatments.

Utility 3
pubmed Dec 1, 2003

Dietary n-3 and n-6 fatty acids alter avian pituitary sensitivity.

Newman. R E RE; Storlien. L H LH; Bryden. W L WL; Kirby. A C AC; Downing. J A JA

In chickens, the type of fat you eat changes how the pituitary gland reacts to a growth‑hormone‑releasing hormone (like sermorelin). A diet high in omega‑6 fats (sunflower oil) made the birds release more GH after a sermone‑type stimulus, while omega‑3 fats (fish oil) blunted the response and slowed GH clearance. Saturated fat (tallow) gave a middle‑of‑the‑road effect.

Utility 3
pubmed Sep 1, 1990

The interaction between clonidine and growth hormone releasing hormone in the stimulation of growth hormone secretion in man.

Suri. D D; Hindmarsh. P C PC; Brain. C E CE; Pringle. P J PJ; Brook. C G CG

The study shows that giving a growth‑hormone‑releasing hormone (like sermorelin) when your body’s own GH levels are already climbing leads to a bigger GH spike, while the drug clonidine works independently of that timing. Prior use of GHRH can dampen the GH response to clonidine, suggesting they act through different pathways.

Utility 3
pubmed Oct 1, 1987

Synergism and diurnal variations of human growth hormone-releasing factor (1-29)NH2 and thyrotropin-releasing factor on growth hormone release in dairy calves.

Lapierre. H H; Petitclerc. D D; Pelletier. G G; Dubreuil. P P; Morisset. J J; Gaudreau. P P; Couture...

In a calf study, giving the growth‑hormone‑releasing peptide (similar to sermorelin) together with a thyroid‑releasing peptide caused a big boost in growth‑hormone spikes, but only when the shots were taken during the light part of the day. When given at night, the boost was much smaller. This shows that timing and possibly pairing with a TRH‑type peptide matter for getting the strongest GH response.

Utility 3
pubmed Jun 1, 1993

Pharmacokinetics of growth hormone-releasing hormone(1-29)-NH2 and stimulation of growth hormone secretion in healthy subjects after intravenous or intranasal administration.

Wilton. P P; Chardet. Y Y; Danielson. K K; Widlund. L L; Gunnarsson. R R

The study shows that the growth‑hormone‑releasing peptide sermorelin can raise GH levels when given by IV or nasal spray. A tiny IV dose (0.25 µg/kg) works, but the nasal route only absorbs 3‑5% of the drug, so you need a much larger dose (about 50 µg/kg) to get a similar GH spike. Repeated nasal doses keep GH up without night‑time suppression, suggesting a convenient, injection‑free way to stimulate GH, though the high dose needed may limit practicality.

Utility 3
pubmed Sep 26, 2003

PEGylation of growth hormone-releasing hormone (GRF) analogues.

Esposito. P P; Barbero. L L; Caccia. P P; Caliceti. P P; D'Antonio. M M; Piquet. G G; Veronese. F M...

The study shows that attaching a PEG5000 chain to the peptide sermorelin (a short version of growth hormone‑releasing hormone) at specific spots (Lys12 or Lys21) makes it last much longer in the bloodstream while still activating the hormone receptor just like the original peptide. In animal tests, these PEG‑modified versions caused higher growth hormone and IGF‑1 responses than regular sermorelin.

Utility 3
pubmed Jul 1, 1995

The effects of high altitude on hypothalamic-pituitary secretory dynamics in men.

Ramirez. G G; Herrera. R R; Pineda. D D; Bittle. P A PA; Rabb. H A HA; Bercu. B B BB

Men who live at about 2,600 meters above sea level release a lot more growth hormone when they get a synthetic GHRH (sermorelin) injection, and their IGF‑1 levels go up too, even though other hormone systems stay mostly the same. This shows that low‑oxygen environments can make the GH‑IGF‑1 axis more responsive.

Utility 3
pubmed Sep 1, 1990

Effects of calcitonin on GH response to pyridostigmine in combination with hGHRH (1-29) NH2 in normal adult subjects.

Giustina. A A; Bodini. C C; Bossoni. S S; Doga. M M; Girelli. A A; Pizzocolo. G G; Wehrenberg. W B W...

The study shows that salmon calcitonin (a hormone used for bone health) reduces the growth hormone boost you get from a GHRH peptide like sermorelin. Taking pyridostigmine, a drug that raises acetylcholine, can increase the GH response to GHRH, but it doesn’t counteract the calcitonin effect. In short, calcitonin can blunt the benefits of GHRH, while pyridostigmine may help a bit if calcitonin isn’t involved.

Utility 3
pubmed May 1, 1989

Response to growth hormone-releasing hormone as evidence of hypothalamic defect in optic nerve hypoplasia.

Leaf. A A AA; Ross. R J RJ; Jones. R B RB; Besser. G M GM; Savage. M O MO

In four kids with optic nerve hypoplasia, standard tests showed growth‑hormone deficiency, but giving them a burst of growth‑hormone‑releasing hormone (GHRH) sparked a hormone response, proving the problem was in the hypothalamus, not the pituitary. One child with almost no pituitary tissue didn’t respond well, while another child improved a lot with daily GHRH injections, which is the most natural way to treat this defect.

Utility 3
pubmed May 26, 2012

Inhibition of GHRH aggravated acetaminophen-induced acute mice liver injury through GH/IGF-I axis.

Wang. Tao T; Hai. Jie J; Chen. Xuehui X; Peng. Hua H; Zhang. He H; Li. Lake L; Zhang. Qinggui Q

In mice, an overdose of acetaminophen hurts the liver and triggers the body to release more growth hormone (GH) and IGF‑1. Blocking the hormone that normally tells the pituitary to release GH (GHRH) makes the liver damage even worse, while giving a strong GHRH‑like drug helps protect the liver. This shows that GHRH activity plays a protective role in liver stress, likely through the GH/IGF‑I and JAK/STAT pathways.

Utility 3
pubmed May 15, 1992

Affinity of human growth hormone-releasing factor (1-29)NH2 analogues for GRF binding sites in rat adenopituitary.

Gaudreau. P P; Boulanger. L L; Abribat. T T

The study looked at how tiny changes to the growth‑hormone‑releasing factor peptide (sermorelin) affect its ability to stick to its receptor. It found that the middle part of the peptide (amino acids 13‑21) is especially important, and that adding fatty groups to the start or removing the end‑cap makes the peptide bind less well and become less stable.

Utility 3
pubmed Mar 27, 1990

Dynamic of the GRF-induced GH response in genetically obese Zucker rats: influence of central and peripheral factors.

Renier. G G; Gaudreau. P P; Deslauriers. N N; Petitclerc. D D; Brazeau. P P

In obese Zucker rats, the ability of a growth‑hormone‑releasing peptide (like sermorelin) to boost GH drops sharply by 8 weeks old, likely because high insulin, fatty acids, and brain somatostatin block the response. This suggests that excess body fat and related metabolic issues can blunt the effects of GH‑releasing drugs.

Utility 3
pubmed 1989

Effects of intranasal calcitonin administration on pituitary GH response to hGHRH (1-29)NH2 in normal adult subjects.

Giustina. A A; Romanelli. G G; Doga. M M; Pizzocolo. G G; Giustina. G G

A small study found that giving salmon calcitonin, either as a nasal spray or injection, sharply cuts the growth hormone boost you get from a direct GHRH stimulus. This means calcitonin can block the effect of GHRH‑based drugs like sermorelin, so using them together could make the GH‑raising benefits weaker.

Utility 3
pubmed 1992

The growth hormone-insulin-like growth factor I axis and renal glomerular function.

Hirschberg. R R; Kopple. J D JD

In rats, raising IGF‑I levels (like what sermorelin does) increased kidney filtration and glomerular size, while lowering IGF‑I reduced filtration. This suggests that boosting IGF‑I can affect kidney function, which matters for long‑term health, but the effects were modest and studied only in animals.

Utility 3
pubmed 1989

Free fatty acids suppress growth hormone, but not luteinizing hormone, secretion in sheep.

Estienne. M J MJ; Schillo. K K KK; Green. M A MA; Boling. J A JA

In sheep, raising blood free‑fatty‑acid levels (like after a high‑fat meal) blocks the normal spikes of growth hormone and makes the hormone less responsive to its releasing signal, while it doesn’t affect luteinizing hormone. This suggests that fatty acids can dampen the body’s ability to release GH, which matters if you’re using GH‑boosting peptides such as sermorelin.

Utility 3
pubmed 1988

Growth hormone (GH) secretion in the conscious rat: negative feedback of GH on its own release.

Clark. R G RG; Carlsson. L M LM; Robinson. I C IC

In rats, giving growth hormone (GH) continuously through an IV reduces the body’s own natural GH bursts, but it doesn’t stop the pituitary from responding when a GH‑releasing signal is added. The feedback seems to happen higher up in the brain, not directly at the pituitary. When the GH infusion stops, the body slowly returns to normal GH release.